SGMO Sangamo Therapeutics

Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases. The company was founded in 1995 in Richmond, California. It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. In September 2018, it had 182 employees. Sandy Macrae is the president. In 2018, Edward Rebar became the senior vice president and chief technology officer of Sangamo.

Company profile

Alexander Macrae
Fiscal year end
Former names
IRS number

SGMO stock data



24 Feb 21
13 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 132.83M 132.83M 132.83M 132.83M 132.83M 132.83M
Cash burn (monthly) 42.69M (positive/no burn) 14.48M 10.8M 1.43M (positive/no burn)
Cash used (since last report) 146.93M n/a 49.83M 37.16M 4.93M n/a
Cash remaining -14.11M n/a 83M 95.67M 127.9M n/a
Runway (months of cash) -0.3 n/a 5.7 8.9 89.3 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
25 Mar 21 Duraibabu Prathyusha Common Stock Payment of exercise Dispose F No No 12.27 345 4.23K 40,790
23 Mar 21 Gary Loeb Common Stock Sell Dispose S No No 13.1713 543 7.15K 83,238
23 Mar 21 Gary Loeb Common Stock Sell Dispose S No No 13.1801 5,000 65.9K 83,781
23 Mar 21 Gary Loeb Common Stock Sell Dispose S No No 13.1032 11,981 156.99K 88,781
23 Mar 21 Gary Loeb Common Stock Option exercise Aquire M No No 11.02 11,981 132.03K 100,762
23 Mar 21 Gary Loeb Stock Option (Right-to-Buy) Common Stock Option exercise Dispose M No No 11.02 11,981 132.03K 238,019
25 Feb 21 Carey Robert Common Stock Grant Aquire A No No 0 8,200 0 23,200
25 Feb 21 Carey Robert Stock Option Common Stock Grant Aquire A No No 11.19 16,400 183.52K 16,400
25 Feb 21 Hillan Kenneth J. Common Stock Grant Aquire A No No 0 8,200 0 23,200
25 Feb 21 Hillan Kenneth J. Stock Option Common Stock Grant Aquire A No No 11.19 16,400 183.52K 16,400

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

54.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 224 206 +8.7%
Opened positions 44 32 +37.5%
Closed positions 26 31 -16.1%
Increased positions 68 55 +23.6%
Reduced positions 69 69
13F shares
Current Prev Q Change
Total value 1.22B 771.58M +58.1%
Total shares 78.14M 81.57M -4.2%
Total puts 1.23M 1M +22.2%
Total calls 2.36M 1.23M +92.5%
Total put/call ratio 0.5 0.8 -36.5%
Largest owners
Shares Value Change
Wasatch Advisors 10.07M $157.18M +41.7%
BLK Blackrock 9.57M $149.28M -3.3%
Vanguard 8.45M $131.92M +4.0%
STT State Street 6.38M $99.51M -9.2%
CS Credit Suisse 3.41M $53.18M +11.9%
GS Goldman Sachs 2.48M $38.66M +34.4%
Dimensional Fund Advisors 2.36M $36.77M +2.7%
Geode Capital Management 1.81M $28.32M +3.2%
JPM JPMorgan Chase & Co. 1.78M $27.82M +81.9%
NTRS Northern Trust 1.44M $22.48M -3.3%
Largest transactions
Shares Bought/sold Change
BLVGF Bellevue 0 -3.85M EXIT
Wasatch Advisors 10.07M +2.96M +41.7%
Great Point Partners 0 -1.59M EXIT
Tang Capital Management 0 -1.58M EXIT
JPM JPMorgan Chase & Co. 1.78M +802.87K +81.9%
Citadel Advisors 601.08K -740.27K -55.2%
STT State Street 6.38M -648.11K -9.2%
GS Goldman Sachs 2.48M +633.78K +34.4%
Voloridge Investment Management 588.62K +588.62K NEW
Two Sigma Investments 1.25M -525.17K -29.5%

Financial report summary

Management Discussion
  • Total revenues consisted of revenues from collaboration agreements and research grants. We anticipate revenues over the next several years will be derived primarily from our collaboration agreements with Biogen, Kite, Novartis, Pfizer and Sanofi as we continue to recognize upfront and milestone payments received under such agreements over time.
  • The increase of $15.8 million in revenues in 2020 compared to 2019 was primarily due to the recognition of upfront license fees of $21.4 million and $4.1 million under our collaboration agreements with Biogen and Novartis entered into in 2020, respectively. In addition, an increase of $6.2 million in recognition of upfront license fee related to our C9ORF72 collaboration agreement with Pfizer due to advancement of the program.
  • These increases were partially offset by a decrease of $12.6 million in revenues related to our hemophilia A collaboration agreement with Pfizer due to a decrease in activities following the IND transfer in December 2019, and a decrease of $3.2 million in license revenue from our collaboration agreement with Sanofi primarily due to a change in estimate driven by a change in project scope and related project cost.
Content analysis
H.S. junior Avg
New words: ABO, ABR, abrogate, adequacy, anesthesiologist, arisen, autism, bacteria, bacterial, ballot, barrier, Bay, Beam, beneficiary, Biden, BioMedical, bold, BreyanziTM, Canada, capsid, celebrate, celebrated, Centric, certified, cessation, CFR, chain, closeout, CMO, coaching, coat, collateral, collateralized, communicable, complaint, concept, Conservancy, contact, convinced, cooperation, copier, corticosteroid, CPRA, Crohn, curb, cutoff, deactivated, deal, DEI, digestive, dignity, disability, discipline, discrimination, disproportionate, diversification, economy, embrace, embraced, embracing, ESRD, ethnicity, etiology, evolution, exceeded, exceeding, exert, extracellular, extreme, eye, feature, fitelparvovec, flora, flourish, foster, Francisco, fresh, fundamental, Gal, gender, geometric, giroctocogene, great, GTP, gut, hamper, harassment, headache, heard, hesitation, hillan, hinder, hinge, honor, hoping, immunosuppression, immunosuppressive, imperative, implicit, incompatibility, incorrect, Indemnity, inflammation, job, kenneth, knowhow, lifted, Lonza, magnitude, malignancy, masking, mathematical, McClung, median, membrane, mental, migrate, mindset, mismatch, mismatched, mission, mistakenly, morbidity, multicenter, nationwide, neurodevelopment, neurodevelopmental, neuropathy, Northern, nurse, Occupational, online, onsite, overactive, overcome, paramount, passionate, pension, pharmacology, pharmacy, philosophy, plane, polyclonal, preconditioning, prejudice, presence, prion, PRNP, proliferation, proof, pseudo, qualification, quarantine, quickly, race, ramped, readout, recession, recipient, regimen, reinforce, remote, remotely, renal, reorganize, repressor, residence, restore, risky, rival, San, scFv, scorecard, sequester, shedding, shelter, signal, signaling, software, soluble, spacer, spatial, speculative, spread, strive, strongly, struggle, subset, suppression, suppressive, surge, surgery, surpassing, survey, synuclein, systematic, talent, talented, Teamwork, thoughtfully, thrive, tie, transmembrane, tunable, ulcerative, unexpectedly, unpacked, upregulate, Urgency, usability, vaccination, versatile, versatility, viability, wellbeing, white, women, workplace, worsening, ZolgensmaTM
Removed: albumin, andChief, antiretroviral, assume, bargaining, blocking, Bulletin, burden, capture, Center, children, circumvent, clear, collective, commenced, conflict, conform, consume, contemplate, continuously, Cowen, creation, daily, decay, depleted, derive, dilly, diminish, elevated, enactment, engraftment, essential, exemption, flow, frame, immunology, importing, inappropriate, Indemnification, infect, infected, inform, Initiative, invent, invention, investigate, investigating, Kathy, land, learning, lifelong, load, lowering, managerial, marketability, master, mice, mimicking, mouse, newly, observed, opportunistic, opposition, organ, organized, partnering, patented, practicing, profile, questionnaire, red, remained, represented, reservoir, resistant, robust, routine, SAB, stephen, sublicensor, succumb, surface, syndrome, technically, TFs, train, undetectable, Utah, validated, validating, weaken, weakened, Yi


Method of Inactivating a Glucocorticoid Receptor Gene In an Isolated Cell
8 Apr 21
Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR.
Methods and compositions for genome engineering
6 Apr 21
Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease.
Modulation of liver genes
30 Mar 21
Described herein are compositions and methods for modulation of gene expression in the liver including modulation of PCSK9, TTR, SERPINA1, KLKB1 and/or HAO1.
FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
30 Mar 21
A method of gene editing or gene stacking within a FAD3 loci by cleaving, in a site directed manner, a location in a FAD3 gene in a cell, to generate a break in the FAD3 gene and then ligating into the break a nucleic acid molecule associated with one or more traits of interest is disclosed.
Methods and Compositions for Treating Huntington's Disease
4 Mar 21
Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.